Author Archives: Jan De Backer

UCSF and FLUIDDA enter into a new research collaboration

Los Angeles, January 5th 2018

FLUIDDA Inc and the University of California, San Francisco (UCSF) are entering into a new research collaboration as of December 2017. Together with the team of Dr. John Fahy (Professor of Medicine in the Division of Pulmonary and Critical Care Medicine, Department of Medicine and investigator in the Cardiovascular Research Institute), FLUIDDA will engage in a project exploring the effects of pathologic mucus gels in lung disease. Dr. Fahy directs a translational research program in asthma and other airway diseases that aims to uncover fundamental disease mechanisms and improve patient treatment. FLUIDDA will apply its innovative computational techniques to understand the effects of pathologic mucus on lung function and on the deposition patterns of inhaled therapeutics.

Dr. Jan De Backer, FLUIDDA’s CEO, commented “We are very excited to embark upon this collaboration with the renowned group of Dr. Fahy. Using our imaging technology to understand the role of mucus in the disease process of asthmatic patients is a challenging but highly interesting topic. Together we believe we can make significant progress in the development of better therapies for patients suffering from lung diseases.”

FLUIDDA opens office in Los Angeles, CA

The opening of an office in Los Angeles (West Hollywood), California, marks the further expansion of FLUIDDA’s global presence. With an increasing number of clients located at the US West Coast, the California office allows FLUIDDA to provide an even better customer experience. “The high concentration of pharmaceuticals and medical device companies, as well as… Continue Reading

FLUIDDA’s IPF Catalyst Challenge Entry

FLUIDDA is excited to join the IPF Catalyst Challenge! Functional Respiratory Imaging (FRI) is a very promising tool for early diagnosis, disease staging and progression and as a sensitive biomarker in drug development trials. As part of the challenge we would like to build a framework to enhance patient care through FRI because we believe… Continue Reading

Introduction to Functional Respiratory Imaging (FRI) for Investors and Market Analysts

For those who cannot attend our event coming Thursday at Flanders House in New York, you are welcome to register for the Webcast via following link:       FLUIDDA is delighted to invite you to a dedicated session discussing her proprietary Functional Respiratory Imaging (FRI) technology and its application in drug and device… Continue Reading

CIRO and FLUIDDA join forces in pursuit of better patient care

At the recent European Respiratory Society conference in Milan a collaboration between CIRO and FLUIDDA materialized in an effort to enhance the rehabilitation of COPD patients. The care of COPD patients is challenging due to the vast heterogeneity of the disease. Especially the severe COPD patients are often difficult to manage and require intensive care… Continue Reading

FLUIDDA’s FRI Technology was used in a Positive Phase II Trial with iNOpulse® for Treatment of Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD)

“Functional Respiratory Imaging (FRI) provided valuable insights throughout the development process of iNO in COPD patients with PH. The therapy was effective in the initial studies and has great potential to improve the lives of these severely affected patients” Dr. J. De Backer, CEO FLUIDDA   Changes in Blood Vessel Volume determined using Functional Respiratory… Continue Reading